• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西格列汀和米格列醇联合治疗对胰岛素治疗的 2 型糖尿病的影响。

Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.

机构信息

Department of Diabetes and Metabolic Medicine, Center Hospital, and Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan,

出版信息

Diabetes Ther. 2012 Nov;3(1):11. doi: 10.1007/s13300-012-0011-x. Epub 2012 Sep 28.

DOI:10.1007/s13300-012-0011-x
PMID:23055336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3508109/
Abstract

INTRODUCTION

To examine the efficacy of sitagliptin and miglitol when added to ongoing insulin treatment in a patient with type 2 diabetes who had undergone partial gastrectomy.

METHODS

Continuous glucose monitoring (CGM) was performed and either sitagliptin or miglitol, or both, were added to fixed-dose insulin therapy. Blood was drawn at 0, 30, 60, and 120 min after breakfast, and C-peptide, glucagon, glucagon-like peptide (GLP)-1, and glucose-dependent insulinotropic peptide (GIP) were measured.

RESULTS

CGM showed that compared to insulin alone, the addition of either sitagliptin or miglitol, or both, to insulin achieved better glucose control. Compared to insulin alone, early postprandial increments in plasma C-peptide levels and suppressed glucagon levels were observed when sitagliptin was added. Glucagon suppression was even more prominent when both sitagliptin and miglitol were added. Compared to insulin alone, GLP-1 levels were higher during the early postprandial stage when sitagliptin or miglitol was added and even higher when both were added. GIP levels decreased when sitagliptin or miglitol, or both, were added to insulin therapy.

CONCLUSION

The authors showed that the addition of sitagliptin or miglitol, or both, was effective in this insulin-treated patient with diabetes who had undergone gastrectomy.

摘要

简介

研究在接受过部分胃切除术的 2 型糖尿病患者中,将西他列汀和米格列醇添加到正在进行的胰岛素治疗中是否有效。

方法

进行连续血糖监测(CGM),并在固定剂量胰岛素治疗中添加西他列汀或米格列醇,或两者都添加。在早餐后 0、30、60 和 120 分钟抽取血液,并测量 C 肽、胰高血糖素、胰高血糖素样肽(GLP)-1 和葡萄糖依赖性胰岛素释放肽(GIP)。

结果

CGM 显示,与单独使用胰岛素相比,添加西他列汀或米格列醇,或两者都添加到胰岛素中,可实现更好的血糖控制。与单独使用胰岛素相比,添加西他列汀时,血浆 C 肽水平的早期餐后增加和胰高血糖素水平的抑制更为明显。当同时添加西他列汀和米格列醇时,胰高血糖素的抑制作用更为明显。与单独使用胰岛素相比,添加西他列汀或米格列醇时,GLP-1 水平在早期餐后阶段更高,当两者都添加时更高。添加西他列汀或米格列醇,或两者都添加到胰岛素治疗时,GIP 水平下降。

结论

作者表明,在接受过胃切除术的胰岛素治疗的糖尿病患者中,添加西他列汀或米格列醇,或两者都添加是有效的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10a/3508109/f1573f745321/13300_2012_11_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10a/3508109/895fab3ebc2e/13300_2012_11_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10a/3508109/f1573f745321/13300_2012_11_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10a/3508109/895fab3ebc2e/13300_2012_11_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b10a/3508109/f1573f745321/13300_2012_11_Fig2_HTML.jpg

相似文献

1
Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.西格列汀和米格列醇联合治疗对胰岛素治疗的 2 型糖尿病的影响。
Diabetes Ther. 2012 Nov;3(1):11. doi: 10.1007/s13300-012-0011-x. Epub 2012 Sep 28.
2
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.一项使用连续血糖监测系统和肠降血糖素相关标志物评估米格列醇和西他列汀治疗 2 型糖尿病疗效的初步研究。
Cardiovasc Diabetol. 2011 Dec 22;10:115. doi: 10.1186/1475-2840-10-115.
3
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.在接受西他列汀治疗的 2 型糖尿病患者中,早餐前给予米格列醇可增加午餐后血浆活性胰高血糖素样肽-1(GLP-1)水平。
Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6.
4
Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.米格列醇、阿卡波糖和西他列汀对2型糖尿病患者血浆胰岛素和肠肽的影响:一项交叉研究。
Diabetes Ther. 2015 Jun;6(2):187-96. doi: 10.1007/s13300-015-0113-3. Epub 2015 Jun 9.
5
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.米格列醇、西他列汀或二者联合对非糖尿病男性患者血糖、胰岛素和肠降血糖素水平的影响。
Endocr J. 2010;57(8):667-72. doi: 10.1507/endocrj.k10e-103. Epub 2010 Jun 1.
6
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.米格列醇对肥胖2型糖尿病患者胰高血糖素样肽-1分泌及食欲感觉的影响。
Diabetes Obes Metab. 2002 Sep;4(5):329-35. doi: 10.1046/j.1463-1326.2002.00219.x.
7
Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study.米格列醇、西他列汀或二者联合治疗的2型糖尿病患者餐后血浆活性胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽波动、骨骼肌质量与体脂质量之间的关系:MASTER研究的二次分析
J Clin Med. 2023 Apr 24;12(9):3104. doi: 10.3390/jcm12093104.
8
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.西格列汀对 1 型糖尿病患者餐后胰高血糖素和 GLP-1 水平的影响:一项由研究者发起的、双盲、随机、安慰剂对照试验。
Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.
9
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.米格列醇与西他列汀对 2 型糖尿病患者餐后血糖和脂蛋白代谢的影响。
Endocr J. 2013;60(7):913-22. doi: 10.1507/endocrj.ej13-0019. Epub 2013 Apr 10.
10
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.米格列醇与阿格列汀对胰岛素治疗的2型糖尿病的相加作用:一项病例研究。
Clin Drug Investig. 2015 Feb;35(2):141-7. doi: 10.1007/s40261-014-0260-8.

引用本文的文献

1
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.四点餐前血糖自我监测用于评估胰岛素和维格列汀治疗的2型糖尿病患者的血糖控制及变异性
Int J Endocrinol. 2015;2015:484231. doi: 10.1155/2015/484231. Epub 2015 Oct 26.
2
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.米格列醇与阿格列汀对胰岛素治疗的2型糖尿病的相加作用:一项病例研究。
Clin Drug Investig. 2015 Feb;35(2):141-7. doi: 10.1007/s40261-014-0260-8.
3
Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study.

本文引用的文献

1
Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes.与未经血浆提取的检测相比,检测肠降血糖素的免疫分析法:日本 2 型糖尿病患者的肠降血糖素分泌。
J Diabetes Investig. 2012 Feb 20;3(1):70-9. doi: 10.1111/j.2040-1124.2011.00141.x.
2
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.一项使用连续血糖监测系统和肠降血糖素相关标志物评估米格列醇和西他列汀治疗 2 型糖尿病疗效的初步研究。
Cardiovasc Diabetol. 2011 Dec 22;10:115. doi: 10.1186/1475-2840-10-115.
3
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
二甲双胍和米格列醇联合基础胰岛素治疗改善空腹和餐后血糖控制:一项初步研究。
Diabetol Metab Syndr. 2014 Mar 31;6:48. doi: 10.1186/1758-5996-6-48. eCollection 2014.
4
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.替格列汀:一种用于治疗 2 型糖尿病的 DPP-4 抑制剂。
Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. doi: 10.2147/DMSO.S35682. Print 2013.
比较米格列醇和伏格列波糖在日本 2 型糖尿病患者混合餐餐后血浆肠降血糖素反应 12 周治疗的效果。
Diabetes Obes Metab. 2012 Mar;14(3):283-7. doi: 10.1111/j.1463-1326.2011.01526.x. Epub 2011 Dec 2.
4
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.1 型糖尿病患者β细胞功能尚存和丧失时内源性和外源性 GLP-1 的抗糖尿病作用。
Diabetes. 2011 May;60(5):1599-607. doi: 10.2337/db10-1790. Epub 2011 Mar 25.
5
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.西格列汀添加治疗对 2 型糖尿病患者胰岛素治疗的疗效和安全性。
Diabetes Obes Metab. 2010 Feb;12(2):167-77. doi: 10.1111/j.1463-1326.2009.01173.x.
6
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.在接受胰岛素治疗的 2 型糖尿病患者中添加阿格列汀可降低 HbA(1C),而不会导致体重增加或低血糖增加。
Diabetes Obes Metab. 2009 Dec;11(12):1145-52. doi: 10.1111/j.1463-1326.2009.01124.x. Epub 2009 Sep 16.
7
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.米格列醇可使日本2型糖尿病患者在摄入混合餐后胰高血糖素样肽-1反应延长并增强,同时降低胃抑肽反应。
Diabet Med. 2009 Feb;26(2):187-8. doi: 10.1111/j.1464-5491.2008.02651.x.
8
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.维格列汀可增强2型糖尿病患者胰岛对高血糖和低血糖的反应性。
J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43. doi: 10.1210/jc.2008-2152. Epub 2009 Jan 27.
9
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.西他列汀在2型糖尿病患者中的安全性和耐受性:一项汇总分析。
BMC Endocr Disord. 2008 Oct 27;8:14. doi: 10.1186/1472-6823-8-14.
10
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Horm Metab Res. 2008 Oct;40(10):727-30. doi: 10.1055/s-2008-1078754. Epub 2008 Jul 2.